KRYS – Krystal Biotech, Inc.
KRYS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
11.71
Margin Of Safety %
18
Put/Call OI Ratio
0.98
EPS Next Q Diff
0.03
EPS Last/This Y
0.93
EPS This/Next Y
1.22
Price
305.85
Target Price
401.25
Analyst Recom
1.25
Performance Q
-8
Upside
-16.6%
Beta
0.65
Ticker: KRYS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | KRYS | 321.17 | 1.17 | 1.15 | 6210 |
| 2026-10-14 | KRYS | 330.59 | 1.18 | 0.03 | 6204 |
| 2026-10-15 | KRYS | 329.88 | 1.15 | 0.07 | 6270 |
| 2026-10-16 | KRYS | 316.58 | 1.16 | 1.05 | 6240 |
| 2026-10-19 | KRYS | 320.27 | 1.51 | 0.00 | 5058 |
| 2026-10-20 | KRYS | 325.56 | 1.14 | 0.24 | 5722 |
| 2026-10-21 | KRYS | 322.14 | 1.13 | 1.00 | 5744 |
| 2026-10-22 | KRYS | 320.13 | 1.12 | 0.06 | 5750 |
| 2026-10-23 | KRYS | 311.32 | 1.12 | 0.01 | 5758 |
| 2026-10-26 | KRYS | 314.92 | 1.11 | 0.15 | 5799 |
| 2026-10-27 | KRYS | 320.87 | 1.10 | 0.03 | 5812 |
| 2026-10-28 | KRYS | 321.56 | 1.10 | 0.80 | 5825 |
| 2026-10-29 | KRYS | 324.27 | 1.10 | 2.72 | 5879 |
| 2026-10-30 | KRYS | 332.43 | 1.09 | 1.08 | 5911 |
| 2026-11-02 | KRYS | 295.74 | 1.10 | 0.37 | 5986 |
| 2026-11-03 | KRYS | 305 | 1.01 | 0.19 | 6448 |
| 2026-11-04 | KRYS | 310.81 | 1.01 | 0.36 | 6481 |
| 2026-11-05 | KRYS | 300.21 | 1.01 | 0.18 | 6468 |
| 2026-11-06 | KRYS | 300.71 | 1.01 | 0.12 | 6469 |
| 2026-11-09 | KRYS | 302.89 | 1.01 | 0.20 | 6481 |
| 2026-11-10 | KRYS | 306.56 | 1.00 | 1.67 | 6466 |
| 2026-11-11 | KRYS | 308.71 | 0.98 | 0.86 | 6531 |
| 2026-11-12 | KRYS | 305.76 | 0.98 | 999.99 | 6541 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | KRYS | 321.67 | -25.6 | 117.7 | 7.74 |
| 2026-10-14 | KRYS | 330.57 | -25.6 | 139.2 | 7.74 |
| 2026-10-15 | KRYS | 329.85 | -25.6 | 138.5 | 7.74 |
| 2026-10-16 | KRYS | 316.61 | -26.0 | 114.2 | 7.70 |
| 2026-10-19 | KRYS | 320.29 | -26.0 | 132.8 | 7.70 |
| 2026-10-20 | KRYS | 320.29 | -26.0 | 132.8 | 7.70 |
| 2026-10-21 | KRYS | 325.60 | -27.3 | 138.8 | 7.62 |
| 2026-10-22 | KRYS | 320.15 | -27.3 | 126.5 | 7.62 |
| 2026-10-23 | KRYS | 311.50 | -27.3 | 119.1 | 7.62 |
| 2026-10-26 | KRYS | 313.70 | -27.9 | 131.3 | 7.59 |
| 2026-10-27 | KRYS | 320.62 | -27.9 | 136.7 | 7.59 |
| 2026-10-28 | KRYS | 321.55 | -27.9 | 137.7 | 7.59 |
| 2026-10-29 | KRYS | 324.27 | -27.9 | 131.7 | 7.59 |
| 2026-10-30 | KRYS | 331.67 | -27.9 | 136.5 | 7.59 |
| 2026-11-02 | KRYS | 295.97 | -27.9 | 89.4 | 7.59 |
| 2026-11-03 | KRYS | 304.96 | -27.9 | 70.0 | 7.59 |
| 2026-11-04 | KRYS | 310.77 | 56.1 | 105.8 | 8.05 |
| 2026-11-05 | KRYS | 300.17 | 56.1 | 86.5 | 8.05 |
| 2026-11-06 | KRYS | 300.83 | 35.4 | 136.5 | 8.00 |
| 2026-11-09 | KRYS | 302.97 | 35.4 | 138.5 | 8.00 |
| 2026-11-10 | KRYS | 306.58 | 30.6 | 140.3 | 8.01 |
| 2026-11-11 | KRYS | 308.82 | 30.6 | 138.4 | 8.01 |
| 2026-11-12 | KRYS | 305.85 | 30.6 | 131.7 | 8.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | KRYS | -3.37 | 3.88 | 13.38 |
| 2026-10-14 | KRYS | -3.37 | 3.88 | 13.38 |
| 2026-10-15 | KRYS | -3.37 | 3.88 | 13.38 |
| 2026-10-16 | KRYS | -3.37 | 3.88 | 13.38 |
| 2026-10-19 | KRYS | -3.37 | 3.87 | 13.38 |
| 2026-10-20 | KRYS | -3.37 | 3.87 | 13.38 |
| 2026-10-21 | KRYS | -3.37 | 3.87 | 13.38 |
| 2026-10-22 | KRYS | -3.37 | 3.87 | 13.38 |
| 2026-10-23 | KRYS | -3.37 | 3.87 | 13.38 |
| 2026-10-26 | KRYS | -3.37 | 3.78 | 13.38 |
| 2026-10-27 | KRYS | -3.37 | 3.78 | 11.31 |
| 2026-10-28 | KRYS | -3.37 | 3.78 | 11.31 |
| 2026-10-29 | KRYS | -3.37 | 3.78 | 11.31 |
| 2026-10-30 | KRYS | -3.37 | 3.78 | 11.31 |
| 2026-11-02 | KRYS | -3.37 | 0.24 | 11.31 |
| 2026-11-03 | KRYS | -3.37 | 0.24 | 11.31 |
| 2026-11-05 | KRYS | -3.37 | 0.24 | 11.29 |
| 2026-11-06 | KRYS | -3.37 | 0.24 | 11.29 |
| 2026-11-09 | KRYS | -3.37 | -0.74 | 11.29 |
| 2026-11-10 | KRYS | -3.37 | -0.74 | 11.29 |
| 2026-11-11 | KRYS | -3.37 | -0.74 | 11.71 |
| 2026-11-12 | KRYS | -3.37 | -0.74 | 11.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.05
Avg. EPS Est. Current Quarter
1.92
Avg. EPS Est. Next Quarter
2.08
Insider Transactions
-3.37
Institutional Transactions
-0.74
Beta
0.65
Average Sales Estimate Current Quarter
129
Average Sales Estimate Next Quarter
139
Fair Value
362.02
Quality Score
90
Growth Score
55
Sentiment Score
58
Actual DrawDown %
20
Max Drawdown 5-Year %
-44.5
Target Price
401.25
P/E
41.51
Forward P/E
32.99
PEG
1.68
P/S
19.27
P/B
6.31
P/Free Cash Flow
29.21
EPS
7.36
Average EPS Est. Cur. Y
8.01
EPS Next Y. (Est.)
9.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
47.91
Relative Volume
0.56
Return on Equity vs Sector %
-10.7
Return on Equity vs Industry %
8.7
EPS 1 7Days Diff
0.4
EPS 1 30Days Diff
0.15
EBIT Estimation
131.7
◆
KRYS
Healthcare
$305.68
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.3
Range 1M
44.2%
Sup Dist
0.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
12.2%
EPS NY
20.8%
52W%
59%
Long-Term Value
Quality companies, undervalued
WATCH
🟡 HOLD
+14.6% upside
Upside
+14.6%
Quality
90
MoS
18%
KRYS — P/E HistoricalBiotechnology
Krystal Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 295
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
KRYS
Latest News
—
Caricamento notizie per KRYS…
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading